The experience of using the atenolol at newborns with tetralogy of Fallot

• Irina N. Maslennikova
• Ekaterina L. Bokeriya
• Dmitriy N. Degtyarev

Abstract

We performed the analysis of an experience of the beta-blocker Atenolol for newborns in the tetralogy of Fallot and right ventricle hypertrophy. We observed five newborns with tetralogy of Fallot when Atenolol was started in the dose of 0.5-1.5 mg/kg/day. The congenital heart disease was diagnosed prenatally, and clinical manifestations as episodes of desaturation and cyanosis were presented.

Results. The hypertrophy of the right ventricle and desaturation episodes have significantly decreased in the therapy of Atenolol. Nevertheless, we have not seen the efficacy of the medication in one case.

Conclusion. We presented the possibility and safeness of the beta-blocker Atenolol in newborns with tetralogy of Fallot and severe hypertrophy of the right ventricle. There were not observed any side effects of the therapy of Atenolol.

Keywords:tetralogy of Fallot, beta-blocker, Atenolol, right ventricle hypertrophy, newborns

References

1. Tennant P.W., Pearce M.S., Bythell M., Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet. 2010; 375 (9715): 649-56. Epub 2010 Jan 19.

2. Jenkins K.J., Correa A., Feinstein J.A., Botto L., Britt A.E., Daniels S.R. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007; 115 (23): 2995-3014. DOI: 10.1161/CIRCULATIONAHA.106.183216.

3. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics - 2007 update. Circulation. 2007; 115 (5): e69-171. DOI: 10.1161/CIRCULATIONAHA.106.179918. Erratum in Circulation. 2007; 115 (5): e172. Circulation. 2010; 122 (1): e9. [corrected to Kissela, Brett]

4. van der Linde D., Konings E.E., Slager M.A., Witsenburg M., Helbing W.A., Takkenberg J.J. Birth prevalence of congenital heart disease worldwide. J Am Coll Cardiol. 2011; 58 (21): 2241-7. DOI: 10.1016/j.jacc.2011.08.025.

5. Reller M.D., Strickland M.J., Riehle-Colarusso T., Mahle W.T., Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008; 153 (6): 807-13. Epub 2008 Jul 26.

6. Report of the New England Regional Infant Cardiac Program. Pediatrics. 1980; 65 (2 Pt 2): 375-461.

7. Becker A.E., Connor M., Anderson R.H. Tetralogy of Fallot: a morphometric and geometric study. Am J Cardiol. 1975; 35: 402-12.

8. Doyle T., Kavanaugh-McHugh A. Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot. URL: https://www.uptodate.com/contents/pathophysiology-clinical-features-and-diagnosis-of-tetralogy-of-fallot .

9. Abe K., Shimada Y., Takezawa J., Oka N., Yoshiya I. Long-term administration of prostaglandin E1: report of two cases with tetralogy of Fallot and esophageal atresia. Crit Care Med. 1982; 10 (3): 155-8.

10. Schranz D., Voelkel N.F. «Nihilism» of chronic heart failure therapy in children and why effective therapy is withheld. Eur J Pediatr. 2016; 175: 44555. DOI: 10.1007/s00431-016-2700-3.

11. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. DOI: 10.1161/CIR.0b013e318223e230.

12. Doyle T., Kavanaugh-McHugh A., Fish F.A. Management and outcome of tetralogy of Fallot. URL: https://www.uptodate.com/contents/management-and-outcome-of-tetralogy-of-fallot/contributors .

13. Maron M.S., McKenna WJ. Hypertrophic cardiomyopathy: medical therapy. URL: https://www.uptodate.com/contents/hypertrophic-cardiomyop-athy-medical-therapy/contributors .

14. Gilligan D.M., Chan W.L., Joshi J., Clarke P., Fletcher A., Krikler S., et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993; 21 (7): 1672-1679. DOI: 10.1016/0735-1097(93)90386-f.

15. Buchhorn R. Beta blockers in children with congenital heart disease before a corrective procedure. Rev Recent Clin Trials. 2014; 9 (2): 61-3.

16. Miyamoto S.D., Stauffer B.L., Nakano S., Sobus R., Nunley K., Nelson P., et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur Heart J. 2014; 35 (1): 33-41. DOI: 10.1093/eurheartj/ehs229.

17. Honey M., Chamberlain D.A., Howard J. The effect of beta-sympathetic blockade on arterial oxygen saturation in Fallot's tetralogy. Circulation. 1964; 30: 501-10.

18. Eriksson B.O., Thoren C., Zetterqvist P. Long-term treatment with propranolol in selected cases of Fallot's tetralogy. Br Heart J. 1969; 31: 37-44.

19. Ponce F.E., Williams L.C., Webb H.M., Riopel D.A., Hohn A.R. Propranolol palliation of tetralogy of Fallot: experience with long-term drug treatment in pediatric patients. Pediatrics. 1973; 52: 100-8.

20. Garson A. Jr, Gillette PC., McNamara D.G. Propranolol: the preferred palliation for tetralogy of Fallot. Am J Cardiol. 1981; 47: 1098-104.

21. Al Habib H.F., Jacobs J.P., Mavroudis C., Tchervenkov C.I., O'Brien S.M., Mohammadi S., Jacobs M.L Contemporary patterns of management of tetralogy of Fallot: data from the Society of Thoracic Surgeons Database. Ann Thorac Surg. 2010; 90 (3): 813-20.

22. Hoffman J.I.E At what age should tetralogy of Fallot be corrected? Cardiol Young. 2017; 27 (4): 625-9. DOI: 10.1017/S104795111600264X.

23. Loomba R.S., Buelow M.W., Woods R.K. Complete repair of tetralogy of Fallot in the neonatal versus non-neonatal period: a meta-analysis. Pediatr Cardiol. 2017; 38: 893-901. DOI. 10.1007/s00246-017-1579-8.

24. Martins I.F., Doles I.C., Bravo-Valenzuela N.J.M., Santos A.O.R., Varella M.S.P. When is the best time for corrective surgery in patients with tetralogy of Fallot between 0 and 12 months of age? Braz J Cardiovasc Surg. 2018; 33 (5): 505-10. DOI: 10.21470/1678-9741-2018-0019.

25. Fanous E., Mogyorosy G. Does the prophylactic and therapeutic use of beta-blockers in preoperative patients with tetralogy of Fallot significantly prevent and treat the occurrence of cyanotic spells? Interact Cardiovasc Thorac Surg. 2017; 25 (4): 647-50. DOI: 10.1093/icvts/ivx135.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)